To scroll text in this page
August 30, 2011
Tokyo, August 30, 2011 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced that it has decided to sell the fixed asset listed below.
1． Details of Fixed Asset to Be Sold
Asset: Property where the Tokyo Research Center was located
Address: Azusawa 1-10, 1-15-1, Itabashi-ku, Tokyo (16,703.21m² in total)
Book Value: JPY90 million (As of end of August 2011)
Sale Price: JPY10.313 billion (Excluding tax)
Cost of Sale: JPY155 million
Profit from Sale: JPY10.067 billion
Purchaser: Sumitomo Realty & Development Co., Ltd.
Transfer Date: Planned for mid-September
2．Reason for Sale
To improve asset efficiency through reduction and liquidation of assets
3． Earnings Impact
An extraordinary profit on the sale of fixed assets totaling JPY10.067 billion is expected to be realized during the second quarter of the current fiscal year ending in March 2012. Although the upfront cash payment is not included in the current fiscal year financial forecast announced in May, there are currently no plans to alter Astellas’ projected forecast.